Systemic effects of BRL 26921 during thrombolytic treatment of acute myocardial infarction.

Abstract

The effects of BRL 26921, an active-site acylated streptokinase-plasminogen complex, on the fibrinolytic and coagulation systems were studied in 13 patients treated for acute myocardial infarction with a short intravenous infusion of 30 mg of the new drug. In 12/13 patients (92%) significant changes were observed in the concentrations of fibrinogen, fibrin(ogen) degradation products, plasminogen, alpha 2-antiplasmin and F VIII:C; all changes indicating a substantial degree of systemic fibrinolysis. In only one patient were no signs of systemic activation of the fibrinolytic system observed. The therapeutic efficacy of the drug was 85% in this study.

• Authors: J J Hoffmann, F J Van Rey, J J Bonnier
• Journal: Thrombosis research (Thromb Res) Vol. 37 Issue 5 Pg. 567-72 (Mar 01 1985) ISSN: 0049-3848 [Print] United States
• PMID: 3920779 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Fibrin Fibrinogen Degradation Products
• Fibrinolytic Agents
• alpha-2-Antiplasmin
• Anistreplase
• Factor VIII
• Fibrinogen
• Plasminogen
• Streptokinase

Topics

• Adult
• Aged
• Anistreplase
• Factor VIII (analysis)
• Female
• Fibrin Fibrinogen Degradation Products (analysis)
• Fibrinogen (analysis)
• Fibrinolytic Agents (therapeutic use)
• Humans
• Male
• Middle Aged
• Myocardial Infarction (drug therapy)
• Plasminogen (therapeutic use)
• Streptokinase (therapeutic use)
• alpha-2-Antiplasmin (analysis)